Genotype-phenotype discrepancy among family members carrying a novel glucokinase mutation: insights into the interplay of GCK-MODY and insulin resistance

Shuhui Ji[1,#], Hua Shu[1,#], Hongqiang Zhao[2,3,#], Yuanyuan Ye[1], Xuan Liu[1], Shanshan Chen[1], Ying Yang[1], Wenli Feng[1], Jingting Qiao[1], Jinyang Zhen[1], Xiong Yang[2,3], Ziyue Zhang[1], Yu Fan[1], Yadi Huang[1], Qing He[1], Minxian Wang[2,3,4,5,6,7,‡], Kunlin Wang[1,‡], Ming Liu[1,‡]

[1] Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, 300052, China

[2] National Genomics Data Center, China National Center for Bioinformation, Beijing, China

[3]Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

[4]College of Future Technology, Sino-Danish College, University of Chinese Academy of Sciences, Beijing, 100049, China.

[5]Department of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

[6]Hubei Provincial Engineering Research Center of Minimally Invasive Cardiovascular

19 Surgery, Wuhan 430071, China

20 [7]Wuhan Clinical Research Center for Minimally Invasive Treatment of Structural

21 Heart Disease, Wuhan 430071, China

22 [#]Authors contribute equally to the work.

23 [‡]To whom correspondence may be addressed. Ming Liu, Department of

24 Endocrinology and Metabolism, Tianjin Medical University General Hospital, #154

25 Anshan Road, Heping District, Tianjin, 300052, China. Email: mingliu@tmu.edu.cn;

26 Kunling Wang, email: zp-sd@126.com; Minxian Wang, email: wangmx@big.ac.cn

27

28

29

30

31

32

33

34

35

36

Abstract

Aims/Hypothesis: Heterozygous inactivating mutations in the glucokinase (GCK) gene are known to cause maturity-onset diabetes of the young (GCK-MODY). We identified a novel variant of uncertain significance (VUS) GCK mutation (c.77A>T, p.Q26L) in two family members presenting markedly different severities of diabetic phenotypes. This study aimed to elucidate the potential diabetogenic effect of GCK-Q26L and to explore the mono- and poly-genetic background attributing to different diabetes phenotypes.

Methods: Whole-exome sequencing (WES) and genetic analyses, including polygenic risk score (PRS) assessments, were performed in three members of a family with early-onset diabetes. To elucidate the impact of the GCK-Q26L mutation on glucose homeostasis, a global knock-in mouse model harboring this mutation in both heterozygous and homozygous states was generated. Insulin content and insulin secretion response to glucose and potassium were evaluated in isolated islets. Furthermore, the effects of dorzagliatin (a glucokinase activator, GKA) and liraglutide (a glucagon like peptide 1 receptor agonist, GLP-1RA) on glucose tolerance and insulin secretion were assessed in GCK-Q26L mutant mice.

Results: The proband, who inherited the GCK-Q26L mutation from her father (presenting with non-progressive, mildly elevated blood glucose), exhibited severe diabetic phenotypes including polydipsia, polyuria, polyphagia, weight loss, and

ketosis, accompanied by significant dyslipidemia. Genetic analyses revealed that the proband's severe phenotypes and metabolic profiles were associated with a high polygenic risk score (PRS) for insulin resistance that was inherited from her mother. Global heterozygous GCK-Q26L knock-in mice showed a mild increased fasting blood glucose, impaired glucose tolerance (IGT), and decreased serum insulin. Homozygous GCK-Q26L mice presented more severe phenotypes compared to their heterozygous counterparts, confirming the diabetogenic nature of the GCK-Q26L mutation. Further analyses indicated that GCK-Q26L did not affect insulin sensitivity and islet insulin content. However, GCK-Q26L blunted islet responsiveness to different glucose concentrations and markedly impaired glucose-stimulated insulin secretion (GSIS) without affecting potassium chloride-stimulated insulin secretion (KSIS) and glucose inhibitory effects on glucagon secretion. Both GKA and GLP-1RA enhanced insulin secretion and improved glucose tolerance in mutant mice.

Conclusions/Interpretation: This study demonstrates that GCK-Q26L is a GCK-MODY causing mutation. The interplay of GCK-Q26L with a high PRS for insulin resistance contributes to severe diabetic phenotypes. The findings not only expend the list of GCK-MODY causing mutations originally classified as VUS mutations, but also provides insights into interactions of GCK-MODY with polygenic risks of type 2 diabetes, highlighting the importance of considering polygenic backgrounds in the assessment and management of monogenic diabetes.

77 Keywords: monogenic diabetes, glucokinase, GCK-MODY, insulin resistance,
78 polygenic risk score (PRS)

79

80 **Research in Context**

81 What is already known about this subject?

82 Heterozygous inactivating mutations in the GCK gene cause GCK-MODY, an
83 autosomal dominant disorder characterized by mild hyperglycemia present from birth.

84 Insulin resistance can be influenced by multiple genetic polymorphisms, contributing
85 to varying diabetes phenotypes.

86 What is the key question?

87 Is the newly discovered GCK mutation pathogenic?

88 Do the interactions between the GCK mutation and PRS for insulin resistance
89 influence the phenotypic variability in patients carrying GCK-MODY?

90 What are the new findings?

91 The study demonstrates GCK-Q26L impairs GSIS and causes diabetes, establishing it
92 as a novel GCK-MODY causing mutation originally classified as a VUS mutation.

93 The GCK-Q26L knock-in mouse line replicates phenotypes of GCK-MODY in
94 humans, establishing it as an excellent model for GCK-MODY.

The phenotypic variability in patients with GCK-MODY can be significantly influenced by high-risk genetic predisposition of type 2 diabetes.

Both GKA and GLP-1RA enhance insulin secretion and improve glucose tolerance in GCK-Q26L mutant mice, suggesting that they are favorite options for treatment of patients with GCK-MODY and insulin resistance.

How might this impact clinical practice in the foreseeable future?

Recognizing atypical presentations of monogenic diabetes influenced by polygenic factors can enhance diagnostic accuracy and personalized management.

Genetic testing and polygenic risk score assessments can help identify patients at higher risk of severe phenotypes, allowing for earlier and more targeted interventions.

Background

Glucokinase (GCK), a key enzyme in the glycolytic pathway, plays a critical role in glucose metabolism. It acts as a glucose sensor in pancreatic β cells and regulates insulin secretion in response to blood glucose levels [1, 2]. The unique kinetic properties of GCK make it ideal for this regulatory role, as it responds to even small changes in glucose concentration within the physiological range [2, 3]. Heterozygous inactivation mutations of GCK are known to cause maturity-onset diabetes of the young type 2 (MODY 2, also known as GCK-MODY), an autosomal dominant form

of diabetes. These GCK inactivation mutations impair enzymatic activity, affecting glucose sensing of pancreatic β cells, resulting in a higher set point for insulin secretion, and therefore leading to mild and non-progressive elevated fasting blood glucose (FBG) from an early age [4, 5]. Notably, unlike other types of diabetes, GCK-MODY does not typically increase the risks of chronic micro- and macrovascular complications of diabetes [6]. Therefore, the current recommendations for the management of GCK-MODY emphasize lifestyle management and regular blood glucose monitoring rather than active treatment with hypoglycemic agents [6, 7]. However, the clinical presentation of GCK-MODY can vary significantly among individuals, even within the same family. The underlying mechanisms for this variability remain incompletely understood.

Insulin resistance associated with multiple genetic and environmental factors is a key feature of type 2 diabetes (T2D) [8]. Recent studies have identified various genetic polymorphisms contributing to insulin resistance, each adding a small risk but cumulatively having a significant impact [9]. A high polygenic risk score (PRS) for insulin resistance aggregates the effect of numerous risk alleles, increasing the likelihood of T2D development [10, 11]. Additionally, a high PRS for T2D may also interact with monogenic diabetes causing mutations, leading to atypical and severe diabetic phenotypes that challenge the traditional approaches for classification and management of different types of diabetes [8, 12-14]. Understanding the interaction between these genetic factors is crucial for developing personalized treatment

strategies [15].

In this study, we identified a novel variant of uncertain significance (VUS) GCK mutation (c.77A>T, p.Q26L) in two members of a family exhibiting markedly different severities of diabetic phenotypes. A global knock-in mouse model established that GCK-Q26L impaired insulin secretion of β cells response to glucose and caused an increase of FBG and an impairment of glucose tolerance, thereby confirming this mutation is a GCK-MODY causing mutation. Genetic analyses revealed the interplay between the GCK-MODY mutation and a high PRS for insulin resistance contributed to the severe diabetic phenotypes in the proband carrying GCK-Q26L. The study not only expends the list of GCK-MODY causing mutations originally classified as VUS mutations, but also highlights genetic bases underlying phenotype heterogeneities of patients with monogenic diabetes.

Materials and Methods

Patients. The clinical information of the proband and her family members was detailed in Table 1, collected and documented in Tianjin Medical University General Hospital. Informed consent was obtained from all family members. The study was approved by the Tianjin Medical University General Hospital Ethics Committee (IRB2017-047-01).

Genetic Testing and Analyses. DNA was extracted from proband's white blood cells

for targeted gene capture, followed by whole-exome sequencing (WES) utilizing massive parallel next-generation sequencing (NGS). The identified GCK gene mutation was further confirmed by Sanger sequencing, the primers for the forward- and reverse-strand were 5'-TGTGGGGGAGATGCCCCG-3' and 5'-ACCAGAGGAGCCAAGGGTGAG-3', respectively. Members of the proband's family (father, mother and grandfather) were recruited and checked for the mutation using Sanger sequencing. Furthermore, the family members (father and mother) also underwent WES sequencing.

Definitions for Insulin Resistance. Insulin resistance (IR) was measured as the ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) as described elsewhere [9, 16-19] (ESM Fig. 4). To correct the potential effect of cholesterol lowering medications, we adjusted the levels of TG and HDL-C before calculating IR with detailed adjustment in ESM Table 4.

Genotype quality control and imputation. The proband trios were genotyped by Affymetrix Axiom whole-genome Asian Screening Array (ASA Array) with calling rate > 99%. Kingship (ESM Table1) and sex (ESM Table2) were further validated with genetically inferred ones. The data was merged with non-close related samples from the 1000 Genomes Project with ambiguous variants (A/T or G/C alleles) removed. This was followed by a series of quality controls in samples with a missingness rate > 5%, or heterozygosity out of 5 standard deviations were excluded,

and variants with a missing rate > 1% or Hardy-Weinberg equilibrium with a P-value < 1 × 10^−6 were excluded. Then, principal component analysis (PCA) was conducted, and ancestry was inferred by the PCA clusters. Finally, the genotype was further imputed on the TOPMed imputation server [20] (ESM Fig. 3), and variants with imputation quality score (INFO) < 0.8 were removed in subsequent analysis.

PRS assessment. We directly utilized the polygenic scores model for insulin resistance developed by Lotta et al.[8] from the PGS Catalog and calculated the PRS for our datasets together with 1000 Genomes Project East Asian samples by PLINK 2.0 [21]. To confirm the association between PRS and IR, we also calculated the PRS for the samples (424,068 passed quality control) from the UK Biobank (ESM Table 3) under application number 89885, following the same procedures. The PRS was further corrected by the value of principal components (PCs) for potential population structure and batch effects and standardized to normal distribution for further statistical analysis.

Mice. We commissioned GemPharmatech Co., Ltd. to create a global knock-in GCK-Q26L mouse model. The Q26L site-directed mutagenesis was introduced in exon 2 of mouse GCK-201, changing the codon for the 26th amino acid from CAG to CTG and inserting MYC before the stop codon (ESM. Fig.1a). All mice were bred on a C57BL/6J background and housed in temperature (22–25 °C) and humidity (55 ± 5%) controlled rooms with a 12-hour light/dark cycle. All animal experimental protocols

were approved by the Internal Animal Welfare Committee at Chu Hsien-I Memorial Hospital (Metabolic Diseases Hospital) of Tianjin Medical University.

Glucose and insulin tolerance. Mice were fasted for 6 hours before intraperitoneal glucose tolerance tests (IPGTT). Glucose was administered via intraperitoneal injection at 2 g/kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60, and 120 minutes using an automated glucose meter (Roche, ACCU-CHEK, Germany). ELISA kits were used to measure plasma insulin (EZassay, China), and glucagon (Ruixin, China). For the intraperitoneal insulin tolerance test (IPITT), after a 4-hour fast, mice received an intraperitoneal injection of 0.7 U/kg body weight of insulin (Aspart, Novo Nordisk A/S, Denmark). Dorzagliatin (Desano, China) and Liraglutide (Solarbio, China) were administered to mice by gavage or intraperitoneal injection, respectively, 90 minutes before the start of the IPGTT.

Measurement of insulin and glucagon secretion. Islet isolation, glucose-stimulated insulin secretion (GSIS), and potassium-stimulated insulin secretion (KSIS) were performed as previously described [22], glucose-inhibited glucagon secretion was performed simultaneously with GSIS. For the dose-dependent effects of glucose on insulin secretion, isolated pancreatic islets were sequentially cultured in Krebs-Ringer bicarbonate HEPES (KRBH) buffer with glucose concentrations of 2.8 mM, 3.3 mM, 4.5 mM, 5.6 mM, and 7 mM for 2 hours each. After incubation, supernatants were collected, and the islets were homogenized. Secreted insulin and islet insulin content

were measured using ELISA kits (EZassay, China). The secretion efficiency was calculated with secreted insulin in the media normalized to islet insulin content.

Islet perfusion assays. Islet perfusion assays were performed as previously described [22]. The liquid input flow rate was 150 μl/min, with samples collected every minute. Insulin secretion at each time point was quantified using the Wide Range Insulin Assay Kit (EZassay, China) according to the manufacturer's instructions.

Western blot analysis. Equal amounts of islet proteins were loaded onto 4-12% NuPage gradient gels (Thermo, USA), while other tissues were loaded onto 12.5% gels (US EVERBRIGHT, China). The antibodies used in this study were as follows: anti-GCK (Cat: A00884-1, BOSTER, China), anti-c-MYC (Cat: RMYC-45A-2, ICL, USA), anti-GAPDH (Cat: AC033, Abclonal, China), anti-insulin (homemade).

Immunofluorescence. Mouse pancreas was fixed, sectioned, and stained with different primary antibodies followed by Alexa-Fluor-conjugated secondary antibodies. The antibodies used in this study were as follows: anti-insulin (homemade), anti-glucagon (Cat: G2654, Sigma, USA), anti-somatostatin (Cat: ab30788, abcam, USA). Fluorescent images were visualized using an Axio Imager M2 microscope (Carl Zeiss, Germany).

Statistics. All experiments were performed independently at least three times. Data are presented as means ± SEM. Statistical analyses were conducted using GraphPad Prism 8 software. An unpaired Student’s t-test was used for data analysis, with a

threshold of $P < 0.05$ to declare statistical significance.

Results

Identification of a novel variant of uncertain significance (VUS) GCK mutation in a family with early onset diabetes. In the clinic, we observed a special case of diabetes. The female proband was diagnosed with diabetes at age teens, presenting with polydipsia, polyuria, polyphagia, weight loss, and ketosis. Her body mass index (BMI) was 22.66 kg/m², and islet autoantibodies were all negative. Initial FBG was 6–7 mmol/L, 2hBG was 15–18 mmol/L, and HbA1c was 113.12 mmol/mol (12.5%). The result of the 75g oral glucose tolerance test (OGTT) confirmed the diagnosis of diabetes and indicated the presence of insulin resistance and inadequate insulin secretion in response to glucose load. (Fig. 1a). She was treated with Metformin (0.5 g TID) and Insulin glargine (18 U QN), with occasional monitoring showing FBG of 5–7 mmol/L and 2hBG of 13–14 mmol/L. She continued this treatment inconsistently, without dietary control, regular exercise, or routine SMBG. After 2.5 years, she discontinued insulin and continued Metformin (0.5 g TID), with occasional FBG readings of 6–7 mmol/L. Five years post-diagnosis, her FBG increased to 7.5–13.2 mmol/L, HbA1c to 132.79 mmol/mol (14.3%), and BMI to 26.76 kg/m². Her regimen was changed to Metformin (0.5 g TID), Insulin aspart (8-6-6 U before meals), and Insulin glargine (12–16 U QN), but glycemic control remained poor, with FBG of 7–

10 mmol/L. Her father was diagnosed with diabetes at thirties, treated with Metformin 0.5 g BID and Vildagliptin 50 mg BID, with FBG of 5–7 mmol/L. Seven years later, his regimen was changed to Metformin 0.5 g TID and occasional Dapagliflozin, maintaining FBG at 6.5 mmol/L and HbA1c at 60.66 mmol/mol (7.7%). Her grandfather was diagnosed with diabetes at fifties, managed with oral hypoglycemic agents. Her mother was found to have pre-diabetes at forties based on blood glucose and HbA1c levels. Clinical details of the proband and her family were summarized in Table 1.

Given the proband's negative islet autoantibodies and family history, we suspected monogenic diabetes and performed genetic screening. DNA sequencing revealed a novel heterozygous missense mutation, c.77A>T, in exon 2 of the GCK gene, resulting in a glutamine-to-leucine substitution at position 26 (p.Q26L), which had not been reported yet. According to American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) in 2015 guidelines, the mutation was classified as a variant of uncertain significance (VUS) with evidence PM1+PM2+PP2. Pedigree analysis showed that the proband's father had the same heterozygous mutation, while the grandfather and mother did not (Fig. 1b, c).

Based on these findings, the proband's diabetes type and the role of the GCK-Q26L mutation in her complex diabetic phenotype remain unclear. However, the father's glycemic profile aligned with typical GCK-MODY characteristics. Therefore, further

experiments were conducted to assess the impact of the GCK mutation on protein function.

GCK-Q26L is a GCK-MODY causing mutation. Since GCK-Q26L was classified as a VUS and the proband presented atypical clinical features of GCK-MODY, it remained to be determined whether GCK-Q26L is a diabetes causing mutation. We therefore established a global knock-in mouse model expressing MYC-tagged GCK-Q26L (ESM Fig. 1a). Western blot confirmed the specific expression of MYC-tagged mutant GCK in the liver and islets in a dose-dependent manner in GCK-Q26L heterozygous (Het) and homozygous (Hom) mice (ESM Fig. 1b). We had monitored body weight (BW) and FBG of mutant and wild-type (WT) male mice for 16 weeks. Although the GCK-Q26L mutation did not affect BW, it caused mild, non-progressive elevation of FBG in Het mice, with further elevation observed in Hom mice (Fig. 2a, b). To investigate whether abnormal circulating levels of insulin or glucagon were associated with elevated FBG, we examined fasting serum insulin and glucagon levels. Our findings showed that although glucagon levels were unaffected, serum insulin levels were decreased in 16-week-old mutant mice (Fig. 2c, d). We therefore performed intraperitoneal glucose tolerance test (IPGTT) and found that Het and Hom mice exhibited significantly impaired glucose tolerance and lower serum insulin levels compared to that of WT mice at 3 weeks of age (Fig. 2e, f). The severities of

295 decreased serum insulin and impaired glucose tolerance did not further worsen in 16-
296 week-old mutant mice (Fig. 2g, h). The phenotype of female mice was similar to that
297 of male mice but less severe (ESM Fig. 2). These data established that GCK-Q26L
298 caused non-progressive mild hyperglycemia representing one of classic clinical
299 features of GCK-MODY, confirming that GCK-Q26L is a GCK-MODY mutation.

300

301 **GCK-Q26L does not affect insulin sensitivity and islet insulin content.** Since GCK
302 is also expressed in hepatocytes, we asked whether GCK-Q26L affected insulin
303 sensitivity. We performed intraperitoneal insulin tolerance test (IPITT) and found that
304 GCK mutant did not affect insulin sensitivity (Fig. 3a, b), suggesting that
305 hyperglycemia was mainly due to decreased circulating insulin. To investigate
306 whether reduced serum insulin in Het and Hom male mice is caused by decreased to
307 islet insulin content or insulin secretion, we measured insulin content by two
308 independent approaches (western blots and insulin enzyme-linked immunosorbent
309 assays, ELISA). Both methods consistently showed no substantial differences in
310 insulin content in islets of Het and Hom mice compared to WT mice (Fig. 3c-f). The
311 ratio of proinsulin-to-insulin was also not affected (Fig. 3f). Immunofluorescence
312 analysis revealed no impact of the mutation on the abundance and intraislet
313 composition of insulin-positive, glucagon-positive, and somatostatin-positive cells
314 among three groups (Fig. 3h). Furthermore, western blot results showed no significant

differences in endogenous GCK protein expression in the islets among the three groups, indicating that the GCK-Q26L did not affect protein levels of endogenous GCK (Fig. 3d, g).

GCK-Q26L impairs glucose-stimulated insulin secretion without affecting potassium-stimulated insulin secretion and glucose-inhibited glucagon secretion. Since the GCK-Q26L caused a decrease of circulating insulin without affecting islet insulin content (Fig. 2-3), we next asked whether it impair insulin secretion. Insulin secretion was monitored in isolated islets exposed to different glucose concentrations (2.8 mM, 3.3 mM, 4.5 mM, 5.6 mM, 7 mM). We found that the curve of glucose concentration-dependent insulin secretion was shifted to right in Het mice (Fig. 4a), suggesting that the glucose threshold for insulin secretion was increased in GCK-Q26L mice. In addition, insulin secretion response to even higher glucose (16.7 mM) was also impaired in Het islets and the response was further diminished in Hom islets (Fig. 4b). Islet perfusion tests with different glucose concentrations further supported these observations (Fig. 4c). However, despite defects in response to glucose, GCK-Q26L did not affect insulin secretion response to potassium in both tests of potassium chloride-stimulated insulin secretion (KSIS) and islet perfusion (Fig. 4d, e). Furthermore, no differences were observed in glucose-inhibited glucagon secretion (GIGS) in Het and Hom mutant mice (Fig. 4f). These data demonstrated that GCK-

335 Q26L impaired the function of GCK as a glucose sensor in β cells, impeding GSIS
336 without affecting KSIS and GIGS.

337

338 **Dorzagliatin restores the glucose threshold for insulin secretion and ameliorates**
339 **glucose tolerance in GCK-Q26L mice.** Dorzagliatin, a novel allosteric glucokinase
340 activator (GKA), improved glycaemic control and was approved in China for the
341 treatment of adult patients with type 2 diabetes [23, 24]. To evaluate the effects of
342 dorzagliatin on insulin secretion and glucose tolerance in GCK-Q26L mice, we firstly
343 treated mice with oral administrations of dorzagliatin, measured fasting blood glucose
344 and insulin levels 90 minutes after treatment, and then performed IPGTT. We found
345 that dorzagliatin significantly decreased FBG and increased fasting insulin levels in
346 both WT, Het, and Hom mutant mice (Fig. 5a, b). IPGTT results further confirmed
347 improvement of glucose tolerance in mutant mice treated with dorzagliatin (Fig. 5c).
348 We further analyzed insulin secretion response glucose and found that dorzagliatin
349 restored the glucose threshold for insulin secretion (Fig. 5d) and improved GSIS (Fig.
350 5e) in GCK-Q26L mutant islets.

351

352 **Liraglutide amplifies insulin secretion response to glucose and ameliorates**
353 **glucose tolerance in GCK-Q26L mice.** Since liraglutide, a glucagon-like peptide-1
354 receptor agonist (GLP-1RA), has an effect of glucose-dependent stimulated insulin

355 secretion, we next asked whether liraglutide could show beneficial effects on insulin
356 secretion and glucose tolerance in GCK-Q26L mice. We conducted similar
357 experiments as dorzagliatin treatment shown in Fig. 5. We found that unlike
358 dorzagliatin, liraglutide did not significantly stimulate insulin secretion in the fasting
359 state both in WT and mutant mice, and only moderately decreased FBG in GCK
360 mutant mice compared with dorazgliatin (Fig. 6a, b). However, liraglutide indeed
361 markedly stimulated insulin secretion and decreased blood glucose 15 minutes after
362 glucose load (Fig. 6c, d), ameliorating overall glucose tolerance (Fig. 6e). In vitro
363 experiments using isolated islets further confirmed that liraglutide improved GSIS
364 (Fig. 6f) and amplified insulin secreation in 5.6 mmol/L glucose (Fig. 6g) in islets
365 from GCK-Q26L mice. Altogether, these results suggest that while both dorzagliatin
366 and liraglutide improve glucose homeostasis, they do so through distinct mechanisms.
367 Dorzagliatin directly enhances the glucose-sensing capability of glucokinase, whereas
368 liraglutide amplifies insulin secretion in response to glucose.

369

370 **A high PRS for insulin resistance is associated with atypical and more severe**
371 **diabetic phenotypes in proband.** The experimental evidence above demonstrates
372 that GCK-Q26L is a GCK-MODY causing mutation. However, although the proband
373 inherited the mutation from her father who presented typical clinical features of GCK-
374 MODY, the proband presented more severe hyperglycemia that did not resemble a

375 classic GCK-MODY (Fig. 1 and Table 1), suggesting that additional factors may
376 contribute to phenotypes of the proband. Indeed, as the disease progressed , the
377 proband became overweight (BMI 26.76 kg/m^2) and developed dyslipidemia with a
378 high Triglyceride (TG) to HDL-cholesterol (HDL-c) ratio, conditions often associated
379 with insulin resistance [19]. Utilizing data from 424,068 individuals in the UK
380 Biobank (UKB), we examined the association between the TG/HDL-c ratio, a
381 surrogate measure of insulin resistance [9, 16-19], with insulin resistance polygenic
382 scores. Results indicated the PRS was significantly associated with the observed
383 TG/HDL-c ratio, that higher PRS levels corresponded with increases in the TG/HDL-
384 c ratio, supporting the relevance of PRS in assessing insulin resistance genetic risk in
385 the population (Fig. 7a). To explore the genetic predisposition of insulin resistance in
386 this family, we conducted a PRS analysis and used the East Asian samples from the
387 1000 Genomes Project samples for evaluate the PRS risk and adjusted for potential
388 population structure confounding through principal component analysis (PCA) (ESM
389 Fig. 5a, b). The PRS analysis of the family indicated the proband inherited a high
390 insulin resistance genetic risk from her mother, who has an IR PRS score ranked in
391 the top 2% in the study population (Fig. 7b). According to previous studies,
392 monogenic risk and polygenic scores may jointly influence the risk of disease [14].
393 These data suggest that the probands' atypical and severe diabetic phenotypes were
394 associated with high PRS for insulin resistance in addition to GCK mutation.

395

Discussion

The identification of the novel GCK-Q26L mutation, originally classified as VUS, in two members of a family with marked differences in PRS for insulin resistance and different severities of diabetes adds to the growing complexities of genetic contributions to the development and progression of diabetes. With multiple independent approaches, we demonstrated that GCK-Q26L did not affect insulin biosynthesis and islet insulin content, but impeded glucose sensing of pancreatic β cells, increasing the threshold of glucose concentration for insulin secretion, impairing GSIS, and therefore causing mild elevated FBG and glucose intolerance. These data established that GCK-Q26L is indeed a pathogenic mutation causing GCK-MODY.

GCK-MODY typically presents with mild hyperglycemia that is often managed without pharmacological intervention due to low risks of diabetes related chronic complications and the limited efficacy of traditional glucose-lowering medications [4, 6]. However, the presence of insulin resistance can complicate the clinical picture, leading to more severe hyperglycemia and necessitating therapeutic intervention. The results from our GCK-Q26L mouse model highlight the potential therapeutic benefits of using GKA and GLP-1RAs in managing diabetes phenotypes influenced by both GCK mutations and polygenic risk factors for insulin resistance. Dorzagliatin is a new a dual-acting GKA that enhances glucokinase activity by binding to its allosteric site,

increasing glucose phosphorylation and insulin secretion, thereby improving glycemic control [23, 25]. In a clinical trial, dorzagliatin directly increases insulin secretion and glucose sensitivity in patients with GCK-MODY, suggesting that it may be able to preserve GCK activity in GCK-MODY [26]. Our data further demonstrated that dorzagliatin restored glucose threshold for insulin secretion and improved GSIS and glucose intolerance in GCK-Q26L mutant mice (Fig, 5d-e). It is worthy to note that dorzagliatin can increase insulin secretion in GCK-Q26L mice and decrease blood glucose even in the fasting state with relatively low FBG in both WT and mutant mice (Fig. 5a-c). However, there is no increased risk of hypoglycemia in a phase 3 clinical trial dorzagliatin [23]. It remains to be determined whether this was caused by extra high dose of dorzagliatin (about 15 times higher dose using in mice in this study than recommend dose for patients with type 2 diabetes) or due to different responses of different species.

In addition to dorzagliatin that directly targets to GCK, GLP-1RAs may also be considered for the management of patients with GCK-MODY due to its beneficial effect on glucose-dependent insulin secretion. Indeed, our data demonstrated that liraglutide enhanced glucose sensing of mutant islets at physiological glucose concentrations and improved GSIS (Fig. 6). Furthermore, one signal administration of liraglutide could significantly decrease FBG of mutant mice without affecting FBG of

436 WT mice and markedly improve glucose tolerance (Fig, 6). These beneficial effects
437 on glucose sensing and insulin secretion along with its role in regulating weight loss
438 and insulin resistance make liraglutide (and may be other GLP1-RAs) an attractive
439 option for the management of GCK-MODY, especially in patients with GCK-MODY
440 with insulin resistance.

441

442 To date, monogenic mutation involved in more than 70 genes have been identified to
443 cause monogenic diabetes. Some of the biggest challenges for early recognition and
444 diagnosis of monogenic diabetes are highly variable for disease penetrance and
445 clinical presentations in patients carrying different mutations in one gene or even the
446 same mutation in the same gene. Accumulating evidence indicates that genetic and/or
447 environmental factors may exacerbate or lessen the conditions, and many VUS can
448 have significant pathogenic effects when combined with other genetic predispositions
449 [4, 27]. In the current study, we found that the proband who carried a GCK-MODY
450 causing mutation inherited from her father, also possessed a high PRS for insulin
451 resistance that may have been inherited in part from her mother, whose PRS for
452 insulin resistance was in top 1.09^{th} percentile (Fig. 7). The elevated PRS may
453 contribute to proband's atypical presentation including more severe hyperglycemia
454 and dyslipidemia, supporting an additive effect that monogenic and polygenic factors
455 may interact. These findings align with recent research indicating that PRS can

456 substantially influence the clinical presentation of monogenic diseases, including
457 diabetes [28, 29]. This dual influence underscores the complexity of diabetes
458 pathogenesis and challenges the traditional dichotomy between monogenic and
459 polygenic diabetes, highlighting the importance of considering polygenic factors even
460 in cases initially attributed to single-gene mutations [30, 31]. Incorporating
461 comprehensive genetic assessments, including PRS, into routine diabetes care could
462 revolutionize how we predict, diagnose, and manage diabetes. Recognizing the role of
463 PRS might help identify individuals at high risk for severe forms of diabetes,
464 facilitating earlier interventions and more personalized management strategies [32].
465 Additionally, understanding the interplay between different genetic factors could lead
466 to the development of targeted therapies that address specific mechanistic pathways
467 involved in the disease [33, 34]. Recent studies have demonstrated the potential of
468 such personalized approaches in improving disease prognosis [35].

469

470 Despite these promising findings, several limitations need to be acknowledged. First,
471 the study's reliance on a mouse model may not fully capture the complexity of human
472 GCK-MODY and its interaction with insulin resistance. While the GCK-Q26L mutant
473 mouse model provides valuable insights, human clinical trials are essential to validate
474 the efficacy and safety of GKA and GLP-1RAs in GCK-MODY individuals with or
475 without insulin resistance. Second, the study did not explore the long-term effects of

these treatments on beta-cell function and overall metabolic health. Longitudinal studies are necessary to understand the potential benefits and risks associated with chronic use of these therapies. Third, the sample size and genetic diversity of the study population were limited. Future research should include larger, more diverse cohorts to ensure the generalizability of the findings. Furthermore, exploring gene-environment interactions will be crucial in elucidating the full impact of monogenic and polygenic factors on the development and progression of monogenic diabetes.

Author contributions

SJ, HS, and HZ designed and conducted experiments and analyzed data; SJ, HS, HZ YY, XL, SC, WF, JQ, JZ, and ZZ conducted experiments; All other authors revised the manuscript critically for important intellectual content. MW discussed project and edited manuscript; ML initiated and oversaw the project, designed the experiments, and wrote the manuscript.

Acknowledgments

The work was supported by the National Key R&D Program (2022YFE0131400 and 2019YFA0802502), and also by the National Natural Science Foundation of China (82220108014). We acknowledge the support of Tianjin Municipal Health Commission (TJWJ2021ZD001), Tianjin Medical University General Hospital Clinical Research Program (22ZYYLCZD02), Tianjin Municipal Science and

Technology Commission (23JCQNJC00680 and 23JCQNJC00670), National Natural Science Foundation of China (82200892, 82301951, and 81800733), Tianjin Municipal Education Commission (2021KJ209), Tianjin Medical University Endocrine and Metabolic Disease the Youth Talent Incubator Program (2024XKNFM13), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-030A), and Tianjin Medical University Clinical Special Disease Research Center - Neuroendocrine Tumor Clinical Special Disease Research Center.

Data availability

Due to local privacy laws and privileged human information, all requests for raw genotyping and clinical data are subject to prior approval from the local IRB. Analysis of the UK Biobank data was performed using application 89885. The UK Biobank data are available to researchers with research inquiries following IRB and UK Biobank approval (https://www.ukbiobank.ac.uk/enableyour-research/apply-for-access).The polygenic scores described in this publication are available for download from the Polygenic Score Catalog (https:// www.pgscatalog.org) under the publication ID PGP000223

Code availability

The manuscript described a pragmatic approach of publicly available software. Additional code is available upon request from the authors.

References

[1] Matschinsky FM (1990) Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 39(6): 647-652. 10.2337/diab.39.6.647

[2] Grimsby J, Sarabu R, Corbett WL, et al. (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301(5631): 370-373. 10.1126/science.1084073

[3] Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51 Suppl 3: S394-404. 10.2337/diabetes.51.2007.s394

[4] Stride A, Vaxillaire M, Tuomi T, et al. (2002) The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 45(3): 427-435. 10.1007/s00125-001-0770-9

[5] Osbak KK, Colclough K, Saint-Martin C, et al. (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30(11): 1512-1526. 10.1002/humu.21110

[6] Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT (2014) Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311(3): 279-286. 10.1001/jama.2013.283980

[7] Chakera AJ, Steele AM, Gloyn AL, et al. (2015) Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care 38(7): 1383-1392. 10.2337/dc14-2769

[8] Lotta LA, Gulati P, Day FR, et al. (2017) Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 49(1): 17-26. 10.1038/ng.3714

[9] Oliveri A, Rebernick RJ, Kuppa A, et al. (2024) Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank. Nat Genet 56(2): 212-221. 10.1038/s41588-023-01625-2

[10] Suzuki K, Hatzikotoulas K, Southam L, et al. (2024) Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature 627(8003): 347-357. 10.1038/s41586-024-07019-6

[11] Khera AV, Chaffin M, Aragam KG, et al. (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50(9): 1219-1224. 10.1038/s41588-018-0183-z

[12] Schroeder P, Mandla R, Huerta-Chagoya A, et al. (2023) Rare variant association analysis in 51,256 type 2 diabetes cases and 370,487 controls informs the spectrum of pathogenicity of monogenic diabetes genes. medRxiv. 10.1101/2023.09.28.23296244

[13] Kingdom R, Beaumont RN, Wood AR, Weedon MN, Wright CF (2024) Genetic modifiers of

549 rare variants in monogenic developmental disorder loci. Nat Genet 56(5): 861-868.
550 10.1038/s41588-024-01710-0

551 [14] Fahed AC, Wang M, Homburger JR, et al. (2020) Polygenic background modifies penetrance
552 of monogenic variants for tier 1 genomic conditions. Nat Commun 11(1): 3635. 10.1038/s41467-
553 020-17374-3

554 [15] McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes.
555 Diabetologia 60(5): 793-799. 10.1007/s00125-017-4210-x

556 [16] Iwani NA, Jalaludin MY, Zin RM, et al. (2017) Triglyceride to HDL-C Ratio is Associated with
557 Insulin Resistance in Overweight and Obese Children. Sci Rep 7: 40055. 10.1038/srep40055

558 [17] McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003) Use of metabolic
559 markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139(10):
560 802-809. 10.7326/0003-4819-139-10-200311180-00007

561 [18] Pantoja-Torres B, Toro-Huamanchumo CJ, Urrunaga-Pastor D, et al. (2019) High
562 triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight
563 healthy adults. Diabetes Metab Syndr 13(1): 382-388. 10.1016/j.dsx.2018.10.006

564 [19] Chiang JK, Lai NS, Chang JK, Koo M (2011) Predicting insulin resistance using the
565 triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc
566 Diabetol 10: 93. 10.1186/1475-2840-10-93

567 [20] Das S, Forer L, Schonherr S, et al. (2016) Next-generation genotype imputation service and
568 methods. Nat Genet 48(10): 1284-1287. 10.1038/ng.3656

569 [21] Purcell S, Neale B, Todd-Brown K, et al. (2007) PLINK: a tool set for whole-genome
570 association and population-based linkage analyses. Am J Hum Genet 81(3): 559-575.
571 10.1086/519795

572 [22] Qiao J, Zhang Z, Ji S, et al. (2022) A distinct role of STING in regulating glucose homeostasis
573 through insulin sensitivity and insulin secretion. Proc Natl Acad Sci U S A 119(7).
574 10.1073/pnas.2101848119

575 [23] Zhu D, Li X, Ma J, et al. (2022) Dorzagliatin in drug-naive patients with type 2 diabetes: a
576 randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 28(5): 965-973.
577 10.1038/s41591-022-01802-6

578 [24] Syed YY (2022) Dorzagliatin: First Approval. Drugs 82(18): 1745-1750. 10.1007/s40265-022-
579 01813-0

580 [25] Haddad D, Dsouza VS, Al-Mulla F, Al Madhoun A (2024) New-Generation Glucokinase
581 Activators: Potential Game-Changers in Type 2 Diabetes Treatment. Int J Mol Sci 25(1).
582 10.3390/ijms25010571

583 [26] Chow E, Wang K, Lim CKP, et al. (2023) Dorzagliatin, a Dual-Acting Glucokinase Activator,

584 Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the
585 Young and Recent-Onset Type 2 Diabetes. Diabetes 72(2): 299-308. 10.2337/db22-0708

586 [27] Richards S, Aziz N, Bale S, et al. (2015) Standards and guidelines for the interpretation of
587 sequence variants: a joint consensus recommendation of the American College of Medical
588 Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5): 405-424.
589 10.1038/gim.2015.30

590 [28] Khera AV, Chaffin M, Wade KH, et al. (2019) Polygenic Prediction of Weight and Obesity
591 Trajectories from Birth to Adulthood. Cell 177(3): 587-596 e589. 10.1016/j.cell.2019.03.028

592 [29] Johansson S, Irgens H, Chudasama KK, et al. (2012) Exome sequencing and genetic testing
593 for MODY. PLoS One 7(5): e38050. 10.1371/journal.pone.0038050

594 [30] Udler MS, McCarthy MI, Florez JC, Mahajan A (2019) Genetic Risk Scores for Diabetes
595 Diagnosis and Precision Medicine. Endocr Rev 40(6): 1500-1520. 10.1210/er.2019-00088

596 [31] Bonnefond A, Semple RK (2022) Achievements, prospects and challenges in precision care
597 for monogenic insulin-deficient and insulin-resistant diabetes. Diabetologia 65(11): 1782-1795.
598 10.1007/s00125-022-05720-7

599 [32] Pearson ER, Velho G, Clark P, et al. (2001) beta-cell genes and diabetes: quantitative and
600 qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase
601 mutations. Diabetes 50 Suppl 1: S101-107. 10.2337/diabetes.50.2007.s101

602 [33] McCarthy MI (2010) Genomics, type 2 diabetes, and obesity. N Engl J Med 363(24): 2339-
603 2350. 10.1056/NEJMra0906948

604 [34] Le Collen L, Froguel P, Bonnefond A (2024) Towards the recognition of oligogenic forms of
605 type 2 diabetes. Trends Endocrinol Metab. 10.1016/j.tem.2024.06.006

606 [35] Inshaw JRJ, Cutler AJ, Crouch DJM, Wicker LS, Todd JA (2020) Genetic Variants Predisposing
607 Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That
608 Function in the Immune System and in Pancreatic beta-Cells. Diabetes Care 43(1): 169-177.
609 10.2337/dc19-0803

610

611

612

613

a

Time (mins)	Glucose (mmol/L)	Insulin (mIU/L)	C-Peptide (ng/mL)
0	6.29	14.80	1.37
30	11.93	21.60	2.22
60	17.20	30.50	3.32
120	18.04	34.60	4.73
180	14.46	29.70	4.89

c



b



Figure 1. Proband with impaired insulin secretion and diabetes carries a GCK missense mutation (c.77A>T, p.Q26L) that was inherited from her father. (**a**) The results of blood glucose, insulin, and C-Peptide of the proband during OGTT performed at the onset of diabetes. (**b**) A missense mutation in GCK gene (c.77A>T, p.Q26L) was identified in the proband and her father by WES confirmed by Sanger sequencing. (**c**) Pedigree analyses showed that GCK-Q26L was inherited from proband's father. Squares represent males and circles represent females. Filled black symbols indicated members affected with diabetes, gray symbol represented the member with the pre-diabetes. The proband was indicated with a black arrow. Where tested, the genotypes of family members were given (N, normal allele; M, mutant allele; NN, normal genotype; NM,

11 heterozygous genotype).



Figure 2. GCK-Q26L causes glucose intolerance in a dose-dependent manner. (**a**, **b**) Body weight (**a**) and fasting blood glucose (**b**) of male mice were measured at 3, 8, 12, 16 weeks of age. WT *vs* Het, WT *vs* Hom, ** P < 0.01, *** P < 0.001, **** P < 0.0001. (**c**) Fasting serum insulin in three-group 16-week-old male mice were measured by ELISA. (**d**) Fasting serum glucagon in three-group 16-week-old male mice were measured by ELISA. (**e**) IPGTT in 3-week-old male mice (2 g/kg i.p.) and the area under curve (AUC) of blood glucose during IPGTT. (**f**) Serum insulin levels in 3-week-old male mice during IPGTT were measured by ELISA, with calculated AUCs. (**g**) IPGTT in 16-week-old male mice (2 g/kg i.p) and the AUC of blood glucose. (**h**) Serum insulin levels in 16-week-old male mice during IPGTT were measured by ELISA, with calculated AUCs. Each data point represents an individual mouse. Values are shown as mean ± SEM. WT *vs* Het, WT *vs* Hom, Het *vs* Hom, *P < 0.05, **** P < 0.0001.



Figure 3. GCK-Q26L did not affect insulin sensitivity, insulin content, and islet cell composition. (**a, b**) IPITT were performed in 16-week-old male mice (0.7 U/kg i.p), (**b**) was (**a**) normalized to the baseline of blood glucose. (**c**) Islet insulin content of 16-week-old male mice was measured by ELISA**.** (**d**) Islets isolated from 10-week-old male mice were directly lysed. Western blots were performed to detect endogenous GCK, MYC-tagged GCK (GCK-MYC), proinsulin and insulin as indicated. GAPDH was used as a loading control. Quantification of insulin (**e**), the ratio of proinsulin to insulin (**f**), and GCK (**g**)**.** (**h**) Representative immunofluorescence images of anti-insulin (red), anti-glucagon (green) and

anti-somatostatin(green) antibodies in pancreatic sections from 12-week-old male mice. Scale bar = 50 μm (n = 3 mice/group). Each data point represents an individual mouse. Values were shown as mean ± SEM.



Figure 4. GCK-Q26L impaired glucose-stimulated insulin secretion without affecting potassium-stimulated insulin secretion and glucose-inhibited glucagon secretion. (**a**) Dose-dependent effects of glucose on insulin secretion of 16-week-old male WT and Het mice. Isolated islets successively incubated in 2.8, 3.3, 4.5, 5.6 and 7 mmol/L glucose. (**b**) Islets isolated from 10-week-old male WT, Het and Hom mice were incubated with 2.8 mmol/L for 1 hour followed by stimulated with either low (2.8 mmol/L) or high (16.7 mmol/L) glucose for 2 hours. Insulin secretion response to low and high glucose were measured. (**c, e**) Dynamic insulin secretion of 10-week-old male WT and Hom mice islets cultured in the perfusion chamber with continues buffer renewal (2.8 mmol/L glucose, 16.7 mmol/L glucose, 2.8 mmol/L glucose, 30 mmol/L potassium), with calculated AUCs. (**d**) Islets isolated from 10-week-old male WT, Het and Hom mice were incubated with 2.8 mmol/L glucose for 1 hour followed by stimulated with either low (3.3 mmol/L) or high (50 mmol/L) potassium for 2 hours. Insulin secretion response to low and high potassium were measured. (**f**) Glucagon secretion measured in isolated islets from 10-week-old male WT, Het and Hom mice when incubated in 2.8 and 16.7 mmol/L glucose. Each data point represents an individual mouse. Values are shown as mean ± SEM. * $P < 0.05$.



Figure 5. Dorzagliatin (GKA) restores the glucose threshold for insulin secretion and ameliorates glucose tolerance in GCK-Q26L mice. (**a-c**) We performed IPGTT on 10-week-old male mice (2 g/kg i.p), and vehicle (0.9% Nacl) or GKA (30 mg/kg) was administered orally to mice 90 minutes before glucose challenge. Blood glucose (**a**) and serum insulin level (**b**) before glucose challenge. (**c**) Blood glucose and AUC of IPGTT. (**d**) Dose-dependent effects of glucose on insulin secretion of 10-week-old male WT and Het mice with or without 30 uM GKA, and the AUC of Insulin secretion. Het *vs* Het-GKA, *P < 0.05. (**e**) Insulin secretion measured in isolated islets from 10-week-old male WT, Het and Hom mice when incubated in 2.8, 16.7 mmol/L glucose and 16.7 mmol/L glucose containing 30 uM GKA. Each data point represents an individual mouse. Values are shown as mean ± SEM. * P < 0.05, ** P < 0.01, **** P < 0.0001.



Figure 6. Liraglutide amplifies insulin secretion response to glucose and ameliorates glucose tolerance in GCK-Q26L mice. (**a, b**) For liraglutide, we conducted experiments similar to those shown in Figure 5 with dorzagliatin, assessing blood glucose (**a**) and serum insulin levels (**b**) in mice that had been treated with dorzagliatin and liraglutide prior to glucose challenge. (**c-e**) show the results of IPGTT with Liraglutide. Blood glucose (**c**) and serum insulin level (**d**) 15 minutes after glucose challenge. (**e**) IPGTT and the AUC of blood glucose. (**f**) Insulin secretion measured in isolated islets from 10-week-old male WT, Het and Hom mice when incubated in 2.8, 16.7 mmol/L glucose and 16.7 mmol/L glucose containing 100 nM Lira. (**g**) Dose-dependent effects of glucose on insulin secretion and the AUC of 10-week-old male WT and Het mice with or without 100 nM Lira, Het *vs* Het-Lira, * $P < 0.05$. Each data point represents an individual mouse. Values are shown as mean ± SEM. * $P < 0.05$ *** $P < 0.001$, **** $P < 0.0001$.



Figure 7. Quality control and PRS score for study samples. (**a**) The distribution of the ratio of triglycerides to HDL cholesterol as a function of quintiles of an insulin resistance (IR) polygenic risk score (PRS) was evaluated in 424,664 UK Biobank samples. The horizontal line in the box indicates the median value, and the top and bottom of the box indicate the upper and lower quartiles, respectively. (**b**) The results of insulin resistance polygenic risk score analysis on case family. The curve denotes the probability density function of the IR PRS scores from the 1000 Genomes Project East Asian samples. Vertical dashed lines indicate the PRS for each family member: the father's position at the top 46.96th percentile, the proband at the top 28.52th percentile, and the mother at the top 1.09th percentile.

Table 1. Clinical features of the family of the proband carrying GCK(Q26L) mutation

	Proband	Father	Mother
Age at diagnosis	Teens	Thirties	/
Gender	Female	Male	Female
BMI at present (kg/m^2)	26.76	25.54	29.78
Clinical symptoms at onset	Polydipsia, polyuria, polyphagia, weight loss and ketosis	found elevated FBG in a physical examination	/
FBG at diagnosis (mmol/L)	6-7	5-7	/
FBG at present (mmol/L)	7.5-13.2	6.5	6.4
HbA1c at diagnosis (mmol/mol)	113.12 (12.5%)	/	/
HbA1c at present (mmol/mol)	132.79 (14.3%)	60.66 (7.7%)	44.26 (6.2%)
Total cholesterol (mmol/L)	5.85	5.44	4.19
Triglycerides (mmol/L)	10.39	0.80	1.11
HDL-cholesterol (mmol/L)	0.74	1.03	0.78
LDL-cholesterol (mmol/L)	3.88	3.90	3.24
Islet autoantibodies	Negative	/	/
Treatment at diagnosis	Metformin 0.5g TID	Metformin 0.5g BID	/

	Insulin glargine：18U QN	Vildagliptin 50mg BID	
Treatment at present	Metformin 0.5g TID Insulin aspart：8-6-6U Insulin glargine：12U QN	Metformin 0.5g BID	/
Complications and comorbidities	No	Diabetic retinopathy (non-proliferative stage)	/

Note: BMI, body mass index; FBG, fasting blood glucose; HDL, high density lipoprotein; LDL, low density lipoprotein; OGTT, oral glucose tolerance test; OHA, oral hypoglycemic agent; Islet autoantibodies, GADA(glutamate decarboxylase antibody)、ICA(islet cell antibody)、IA-2A(protein tyrosine phosphatase-like protein antigen)、ZnT8A(Zinc transporter 8 antibody)；TID, ter in die; BID, bis in die; QN, quāque nocte; "/", none or not provided.